October 2010
Oct 13, 2010 • 5:30PM - 7:30PM
Diabetes, the leading cause of kidney failure in adults throughout the world, strains budgets for health care denying treatment by dialysis or kidney transplantation to the large majority of those afflicted. Initially, a reason for exclusion from Medicare treatment in the 1970s, diabetes has continuously expanded to account for 44.6% of incident patients with treatable causes of irreversible kidney failure. Both dialysis and kidney transplantation are unavailable due to cost in developing nations. It follows that prevention as a management strategy coupled with a quest for potential near-term inexpensive future therapies that may preempt or minimize diabetic complications is a major objective. Early evidence indicates that in those with progressive kidney disease, normalizing high blood pressure and the blood glucose level decreases the proportion (rate) of diabetic individuals in the United States who develop kidney failure. This "good news" underlies formulation of a workable, well tolerated means of first line therapy applicable to nearly all persons afflicted with diabetes.
Registration Options:
Free / Free
Register
Edward N. Gibbs Lecture and Award in Nephrology
Location: 1216 Fifth Avenue at 103rd Street New York, NY 10029
Speakers: Eli A. Friedman, M.D., Distinguished Teaching Professor of Medicine
This event sponsored by: The New York Academy of Medicine
Speakers: Eli A. Friedman, M.D., Distinguished Teaching Professor of Medicine
This event sponsored by: The New York Academy of Medicine
Diabetes, the leading cause of kidney failure in adults throughout the world, strains budgets for health care denying treatment by dialysis or kidney transplantation to the large majority of those afflicted. Initially, a reason for exclusion from Medicare treatment in the 1970s, diabetes has continuously expanded to account for 44.6% of incident patients with treatable causes of irreversible kidney failure. Both dialysis and kidney transplantation are unavailable due to cost in developing nations. It follows that prevention as a management strategy coupled with a quest for potential near-term inexpensive future therapies that may preempt or minimize diabetic complications is a major objective. Early evidence indicates that in those with progressive kidney disease, normalizing high blood pressure and the blood glucose level decreases the proportion (rate) of diabetic individuals in the United States who develop kidney failure. This "good news" underlies formulation of a workable, well tolerated means of first line therapy applicable to nearly all persons afflicted with diabetes.
Registration Options:
Free / Free
Register
If paying by check, please mail to:
The New York Academy of Medicine
Education & Conference Center
1216 Fifth Avenue
New York, NY 10029
Fax: 212-987-4735
